After that Q3 dip, AbbVie's FDA approval is the bullish fuel it needed. 🚀 The stock is rebounding hard, breaking above key moving averages on solid volume. RSI is energetic but not overheated. Institutions are piling in, and the chart shows a clear reversal. This is a BUY. The healthcare rotation is real. #BiopharmaBounce

"FDA approval for AbbVie’s new lung cancer drug? Big win! 🎉 But hold the confetti—class action lawsuits are raining on the parade. 📉 Technically, the stock’s bouncing off recent lows with RSI neutral (48.4), and the 9-day WMA is sneaking above the 21-day. Volume’s decent, but not screaming conviction. Chart’s messy—like a toddler’s crayon masterpiece. Verdict: HOLD for now. Let the legal dust settle. #ABBVdrama ☕"